Femme et Homme
- | Pays :
- Norway
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to evaluate the proportion of responders (that is, greater than or equal to [>=] 30 percent reduction from Baseline in blood phenylalanine [Phe] level) to treatment with Kuvan® (sapropterin dihydrochloride) 20 milligram per kilogram per day (mg/kg/day) for 28 days.
Critère d'inclusion
- Phenylketonuria